The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “unicorn” status secured a ...

Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million ...

The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

With their promise to transform disease trajectories, cell and gene therapies (CGTs) are bringing new hope to patients with ...